Patents Assigned to HAIHE BIOPHARMA CO., LTD.
  • Patent number: 11661421
    Abstract: The invention provides an indolizine compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method and a use thereof. The indolizine compound has an inhibitory effect on wild-type and/or mutant EZH2 or EZH1, and is expected to be developed into a novel drug for anti-tumor or for the treatment of autoimmune diseases.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: May 30, 2023
    Inventors: Xuxing Chen, Yi Chen, Ying Huang, Meiyu Geng, Qiong Zhang, Jian Ding, Yucai Yao, Qianqian Shen, Yanyan Shen